Simultaneous RP-HPLC estimation of cilnidipine and telmisartan incombined tablet dosage form

This paper describes a simple, accurate, and validated reverse-phase high-performance liquid chromatographic method for the simultaneous quantification of Telmisartan and Cilnidipine as the bulk drug and in tablet dosage forms. Separation was carried out on Jasco HPLC system equipped with HiQ sil C18 HS column (250 × 4.6 mm i.d.) and PDA detector using Methanol: 40 mM Potassium dihydrogen ortho phosphate buffer (pH 3) (90:10, v/v)) as the mobile phase, and detection was carried out at 245 nm. Results were linear in the range of 1-10 μg mL-1 for Cilnidipine and 5-30 μg mL-1 for Telmisartan. The method was successfully applied for the analysis of drugs in pharmaceutical formulation. Results of the analysis were validated statistically and by recovery studies